866-997-4948(US-Canada Toll Free)

Transitional Cell Cancer (Urothelial Cell Cancer) - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Jul 2013

Category :

Cancer

No. of Pages : 55 Pages


Global Markets Directs, Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, H2 2013, provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Transitional Cell Cancer (Urothelial Cell Cancer). Transitional Cell Cancer (Urothelial Cell Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Transitional Cell Cancer (Urothelial Cell Cancer).
  • A review of the Transitional Cell Cancer (Urothelial Cell Cancer) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Transitional Cell Cancer (Urothelial Cell Cancer) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Transitional Cell Cancer (Urothelial Cell Cancer).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Transitional Cell Cancer (Urothelial Cell Cancer) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Transitional Cell Cancer (Urothelial Cell Cancer) Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Transitional Cell Cancer (Urothelial Cell Cancer) 7
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Products under Development by Companies 12
Companies Involved in Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Development 13
Bristol-Myers Squibb Company 13
Boehringer Ingelheim GmbH 14
Eli Lilly and Company 15
Novartis AG 16
Spectrum Pharmaceuticals, Inc. 17
Innate Therapeutics Limited 18
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
brivanib alaninate - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
volasertib - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ramucirumab - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
pralatrexate - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
dovitinib lactate - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
MIS-416 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Drug Profile Updates 40
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Discontinued Products 47
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics - Dormant Products 48
Transitional Cell Cancer (Urothelial Cell Cancer) Product Development Milestones 49
Featured News & Press Releases 49
May 31, 2013: Dendreon Announces Presentation Of DN24-02 Data At 2013 ASCO Annual Meeting 49
May 23, 2013: Aeterna Zentaris To Present Posters On Phase I And Phase II Trials With AEZS-108 In Prostate And Breast Cancer At Upcoming ASCO Meeting 49
May 22, 2013: OncoGenex Announces Multiple Trials In Progress Presentations On OGX-427 At 2013 ASCO Annual Meeting 50
Feb 13, 2013: Dendreon To Present New Data On Provenge At 2013 ASCO Genitourinary Cancers Symposium 51
May 16, 2012: Sanofi To Present Abstracts On Jevtana At 2012 American Society Of Clinical Oncology Annual Meeting 52

Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Table


Number of Products Under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2013 7
Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Comparative Analysis by Mid Clinical Stage Development, H2 2013 10
Comparative Analysis by Early Clinical Stage Development, H2 2013 11
Products under Development by Companies, H2 2013 12
Bristol-Myers Squibb Company, H2 2013 13
Boehringer Ingelheim GmbH, H2 2013 14
Eli Lilly and Company, H2 2013 15
Novartis AG, H2 2013 16
Spectrum Pharmaceuticals, Inc., H2 2013 17
Innate Therapeutics Limited, H2 2013 18
Assessment by Monotherapy Products, H2 2013 19
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Stage and Molecule Type, H2 2013 23
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Drug Profile Updates 40
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Discontinued Products 47
Transitional Cell Cancer (Urothelial Cell Cancer) Therapeutics Dormant Products 48

List of Chart


Number of Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer), H2 2013 7
Products under Development for Transitional Cell Cancer (Urothelial Cell Cancer) – Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Mid Clinical Stage Products, H2 2013 10
Early Clinical Stage Products, H2 2013 11
Assessment by Monotherapy Products, H2 2013 19
Assessment by Route of Administration, H2 2013 20
Assessment by Stage and Route of Administration, H2 2013 21
Assessment by Molecule Type, H2 2013 22
Assessment by Stage and Molecule Type, H2 2013 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *